Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

Taroh Satoh, Kyung Hee Lee, Sun Young Rha, Yasutsuna Sasaki, Se Hoon Park, Yoshito Komatsu, Hirofumi Yasui, Tae You Kim, Kensei Yamaguchi, Nozomu Fuse, Yasuhide Yamada, Takashi Ura, Si Young Kim, Masaki Munakata, Soh Saitoh, Kazuto Nishio, Satoshi Morita, Eriko Yamamoto, Qingwei Zhang, Jung mi KimYeul Hong Kim, Yuh Sakata

Research output: Contribution to journalArticlepeer-review

73 Citations (Scopus)

Abstract

Background: This multicenter, randomized phase II trial was conducted to compare the efficacy and safety of nimotuzumab plus irinotecan (N-IRI) versus irinotecan alone (IRI) in patients with advanced gastric cancer (AGC) showing disease progression after previous 5-fluorouracil-based therapy. Methods: Irinotecan-naive patients (n = 82) received N-IRI (nimotuzumab 400 mg weekly plus irinotecan 150 mg/m2 biweekly) or IRI (irinotecan 150 mg/m2 biweekly) until disease progression. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), response rate (RR), safety, tolerability, and the correlation between efficacy and tumor epidermal growth factor receptor (EGFR) expression. Results: Of 83 patients, 40 and 43 patients were randomly assigned to the N-IRI and IRI groups, respectively. In the N-IRI/IRI treatment group, median PFS was 73.0/85.0 days (P = 0.5668), and median OS and RR at 18 months were 250.5/232.0 days (P = 0.9778) and 18.4/10.3 %, respectively. Median PFS and OS in the EGFR 2+/3+ subgroups were 118.5/59.0 and 358.5/229.5 days, respectively. The RR was 33.3/0.0 % in the N-IRI/IRI treatment group. The incidence of grade 3 or higher adverse events was 77.5/64.3 %. No adverse events of grade 3 or higher skin rash or grade 3 or higher infusion-related reaction were reported. Conclusions: There was no superiority of N-IRI over IRI alone in terms of PFS in 5-fluorouracil-refractory AGC patients. However, N-IRI showed potential improvement in the EGFR 2+/3+ subgroup based on improved RR, PFS, and OS.

Original languageEnglish
Pages (from-to)824-832
Number of pages9
JournalGastric Cancer
Volume18
Issue number4
DOIs
Publication statusPublished - 2015 Oct 25

Bibliographical note

Funding Information:
We thank all the patients, their families, and the institutions involved in this study. The authors also thank the following individual board members for their contributions to this report: Independent Data Monitoring Committee, Keiichi Nagao, Noriyuki Masuda, Ichinosuke Hyodo, Baek-Yeol Ryoo, Young Iee Park, and Hong Suk Song; Efficacy Evaluation Committee, Atsushi Sato, Junji Tanaka, and Dae Young Zang; and Medical Advisors, Yutaka Ariyoshi and Kiyohiko Hatake. This trial was supported by a grant from Daiichi Sankyo Co., Ltd., Japan, and Kuhnil Pharm. Co., Ltd., Republic of Korea.

Funding Information:
T. Satoh, Y. Komatsu, Y. Yamada, and M. Munakata received research funding and honoraria from Daiichi Sankyo. Y.H. Kim received research funding and an honorarium from Kuhnil Pharm. K. Yamaguchi, N. Fuse, T. Ura, and S. Saitoh received research funding from Daiichi Sankyo. H. Yasui and S. Morita received honoraria from Daiichi Sankyo. Y. Sasaki, K. Nishio, and Y. Sakata received research funding, honoraria, and expert testimony from Daiichi Sankyo. K.H. Lee, S.Y. Rha, S.H. Park, T.Y. Kim, and S.Y. Kim have no conflicts of interests to declare.

Publisher Copyright:
© 2014, The Author(s).

All Science Journal Classification (ASJC) codes

  • Oncology
  • Gastroenterology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer'. Together they form a unique fingerprint.

Cite this